SCHEMBL3823391

SCHEMBL3823391

CC(C)c1nc2ccc(Cl)cc2c(=O)n1C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
RXFP1 Q9HBX9 3/20 0.47
KDM4E B2RXH2 3/20 0.46
HTT P42858 2/20 0.46
LMNA P02545 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
MAPT P10636 2/20 0.43
MAPK1 P28482 1/20 0.43
NPC1 O15118 2/20 0.42
HTR3A P46098 2/20 0.42
HRH4 Q9H3N8 2/20 0.42
CYP2D6 P10635 1/20 0.42
HSD17B10 Q99714 1/20 0.41
FABP3 P05413 1/20 0.41
FABP4 P15090 1/20 0.41
FABP5 Q01469 1/20 0.41
CYP3A4 P08684 1/20 0.41
TDP1 Q9NUW8 1/20 0.40
RAB9A P51151 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3701531 0.84 MEN1 (0.46) MEN1KMT2AKDM4EHTTLMNA
SCHEMBL23212291 0.80 KMT2A (0.43) MEN1KMT2ARXFP1KDM4EHTT
SCHEMBL23212293 0.80 KMT2A (0.43) MEN1KMT2ARXFP1KDM4EHTT
SCHEMBL9919074 0.80 NPC1 (0.54) MEN1KMT2ARXFP1KDM4EHTT
SCHEMBL3825703 0.78 TRPV1 (0.50) MEN1KMT2ATDP1
SCHEMBL7014741 0.78 MEN1 (0.49) MEN1KMT2ARXFP1KDM4EHTT
SCHEMBL15457094 0.78 HTR3A (0.43) NPC1HTR3AHRH4CYP2D6HSD17B10
SCHEMBL6979700 0.78 KDM4E (0.60) MEN1KMT2ARXFP1KDM4EMAPT
SCHEMBL16000136 0.78 PTPN1 (0.43) MEN1KMT2AKDM4EMAPTNPC1
SCHEMBL15457112 0.77 LMNA (0.42) MEN1KMT2AKDM4ELMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8642609-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-02-04 US disclosed
US-8642609-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-02-04 US disclosed
US-8642609-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-02-04 US disclosed
EP-1646615-B1 PYRIMIDINE DERIVATIVES AS MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMA (US) 2009-08-26 EP disclosed
EP-1646615-B1 PYRIMIDINE DERIVATIVES AS MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMA (US) 2009-08-26 EP disclosed
EP-1646615-A1 PYRIMIDINE DERIVATIVES AS MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS Vertex Pharmaceuticals Incorporated (US) 2006-04-19 EP disclosed
US-20050059687-A1 Modulators of ATP-Binding Cassette transporters VERTEX PHARMACEUTICALS INCORPORATED 2005-03-17 US disclosed
WO-2004111014-A1 PYRIMIDINE DERIVATIVES AS MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMACEUTICALS INCORPORATED (US) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059687-A1 Modulators of ATP-Binding Cassette transporters CFTR, ABCB1, ABCC2 MEN1 4698/4885KMT2A 4344/4885RXFP1 1324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.